{"id":454400,"date":"2021-03-10T01:03:29","date_gmt":"2021-03-10T06:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454400"},"modified":"2021-03-10T01:03:29","modified_gmt":"2021-03-10T06:03:29","slug":"sequana-medical-notice-of-2020-full-year-results-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/","title":{"rendered":"Sequana Medical Notice of 2020 Full Year Results and Business Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GHENT, Belgium, March  10, 2021  (GLOBE NEWSWIRE) &#8212; <strong>Sequana Medical NV (Euronext Brussels: SEQUA)<\/strong>, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021.<\/p>\n<p align=\"justify\">The management team will host a conference call with live webcast at 02:00 pm CET \/ 08:00 am EST on the day of the results.<\/p>\n<p align=\"justify\">The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Twtex1bT-BWQDwltK_sgiT_1E5toKp9ZH-R5-TPwDg63H8Volywxp9G9BaTY-G-XDroQYDbUYCxNgSLfhrAW3yMBACN1YuPWwFi5U-iuGi1n8Ckslf9PDr0YwVvgrWUTRPdSJ3qZpliltf0bsL09v_FhHVS9vyTavGrSrrv8QMOlc0c04Q53ypjaEJgDYTkjzWpWemgxmKPJwLMFe63rNg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>. To participate in the Q&amp;A, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ud39pCNpJOQ4ztgsHgL_ZNtm5GXY3r6EZv3s9uofPhjFyeCXT0WuO8BBv0svzMMjmRIb3VeR2KreGft9DQUBDAU6YUxk-yfZZjbcEASb7ec5Q7bmYNnVRMfAg03AxYupIebYFSDa4Zk92S4SfMv5FNwR7-CUsHgPzHTTijRCnh6iyMOBKiGjolb5F-4BwSYeHvcPADBBcclMXhRWs85jp7RODtzFSgxUbQYHjQZvSauIgBB3wFEAZAwSrUW4tJd5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_KNg7II4UMMZDGB4a17PUHaSpH_FkDZpJXQi8d4okU6pbs5jSzdaNhCpg8BPA1Z9J7ophYqCbdaaGq3ikNIg1p1kobzcVMqk8PRwwRoUEvi42lDJ0YFG0rugljerSWPn\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">website<\/a> shortly thereafter.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact: <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Sequana Medical\u00a0<br \/><\/strong>Lies Vanneste <br \/>Director Investor Relations <br \/>Tel: +32 498 05 35 79 <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vEQkk39jyqoqQPmcMAEfz4uOzkD-Yj8cpOweyg7EdLCIEaxyN6AicYZ1nG-X9CR0qtMCwyJ78L7c55d0rHQPXjzN5fwaojfhBk2HCxOE3ZI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>IR@sequanamedical.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>LifeSci Advisors\u00a0<br \/><\/strong>Chris Maggos <br \/>Tel: +41 79 367 6254 <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j1jG4TWUkedGXr4uMDNUBZyph7Ub_00oMDh3Vyoxd-IFbuVaJg2IjZsHRdT9HOYlrnwlcYBF4c2MFIUwhWiQOxS-JdPuu8iL31BoyldU_To=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>chris@lifesciadvisors.com<\/u><\/a>\u00a0 \u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Sequana Medical<\/strong>\n      <\/p>\n<p align=\"justify\">Sequana Medical is a commercial stage medical device company developing the <strong>alfa<\/strong>pump<sup>\u00ae<\/sup> platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the <strong>alfa<\/strong>pump resulting from NASH-related cirrhosis is forecast to exceed \u20ac3 billion annually within the next 10-20 years. The heart failure market for the <strong>alfa<\/strong>pump DSR (Direct Sodium Removal) is estimated to be over \u20ac5 billion annually in the U.S. and EU5 by 2026. Both indications leverage Sequana Medical\u2019s <strong>alfa<\/strong>pump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.<\/p>\n<p align=\"justify\">In the U.S., the company&#8217;s key growth market, the <strong>alfa<\/strong>pump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study. This study is intended to support a future marketing application of the <strong>alfa<\/strong>pump in the U.S. and Canada. In Europe, the <strong>alfa<\/strong>pump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 <strong>alfa<\/strong>pump systems have been implanted to date. Building on its proven <strong>alfa<\/strong>pump platform, Sequana Medical is developing the <strong>alfa<\/strong>pump DSR<sup>\u00ae<\/sup>, a breakthrough, proprietary approach to fluid overload due to heart failure. Clinical proof-of-concept was achieved in a first-in-human single dose DSR<sup>\u00ae<\/sup> study and further supported by strong interim safety and efficacy results from the ongoing repeated dose <strong>alfa<\/strong>pump DSR study (RED DESERT) in heart failure patients.<\/p>\n<p align=\"justify\">Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=07g7kqiuH-KYNtXDEhnuOSKdcTChylRKLAFQKBomepK7TAX9z4WLK5uBPDw4800m8zyCEex6NuzajpeC6kI3ZtuUujINWrA-dteuMC0PXp8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sequanamedical.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Important Regulatory Disclaimers<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>The\u00a0<\/em><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump<sup>\u00ae<\/sup> system is not currently approved in the United States or Canada. In the United States and Canada, the\u00a0<\/em><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump\u00ae system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see\u00a0<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jLwqpIhGCL9eyoSft45pN5s46Y7w3pnco11qXPe1rkTeQrUdqknv4Lj7P_SftXWceWpr4NofTzADDsV_bwdqqK_h_ME6FG1h8-Q-yewpcDg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <em>www.poseidonstudy.com<\/em><br \/>\n        <\/a><br \/>\n        <em>. The DSR<sup>\u00ae<\/sup> therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR<sup>\u00ae<\/sup> therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR<sup>\u00ae<\/sup> therapy and ongoing investigations with the\u00a0<\/em><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump<sup>\u00ae<\/sup> system in Europe, the United States or Canada. DSR<sup>\u00ae<\/sup> and <\/em><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump DSR<sup>\u00ae<\/sup> are registered trademarks in Benelux.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Forward-looking statements<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Note:<\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump<sup>\u00ae<\/sup> is a registered trademark. DSR<sup>\u00ae<\/sup> and <\/em><br \/>\n        <strong><br \/>\n          <em>alfa<\/em><br \/>\n        <\/strong><br \/>\n        <em>pump DSR<sup>\u00ae<\/sup> are registered trademarks in the Benelux.<\/em>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/47adabaa-f51d-4bf8-a25b-7e269373fd6e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) &#8212; Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live webcast at 02:00 pm CET \/ 08:00 am EST on the day of the results. The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&amp;A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sequana Medical Notice of 2020 Full Year Results and Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) &#8212; Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live webcast at 02:00 pm CET \/ 08:00 am EST on the day of the results. The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&amp;A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted &hellip; Continue reading &quot;Sequana Medical Notice of 2020 Full Year Results and Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T06:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sequana Medical Notice of 2020 Full Year Results and Business Update\",\"datePublished\":\"2021-03-10T06:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/\"},\"wordCount\":758,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/\",\"name\":\"Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\",\"datePublished\":\"2021-03-10T06:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-notice-of-2020-full-year-results-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sequana Medical Notice of 2020 Full Year Results and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk","og_description":"GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) &#8212; Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live webcast at 02:00 pm CET \/ 08:00 am EST on the day of the results. The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&amp;A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted &hellip; Continue reading \"Sequana Medical Notice of 2020 Full Year Results and Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T06:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sequana Medical Notice of 2020 Full Year Results and Business Update","datePublished":"2021-03-10T06:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/"},"wordCount":758,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/","name":"Sequana Medical Notice of 2020 Full Year Results and Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==","datePublished":"2021-03-10T06:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzEzNCM0MDU1OTQwIzUwMDA2NjM3Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-notice-of-2020-full-year-results-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sequana Medical Notice of 2020 Full Year Results and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}